Grifols
Grifols receives FDA approval for new plasma-related facility in Clayton
Grifols, a global leader in plasma medicines, has received approval from the U.S. Food and Drug Administration for its new immunoglobulin (Ig) purification and filling facility at its Clayton manufacturing campus, one of the world’s largest sites for producing plasma-derived medicines.
Read More
Private equity veteran replaces Grifols longtime chair Victor Grifols Roura
Life science firm Grifols, which has a growing presence in Johnston County, has a new executive chairperson: Veteran private equity executive Steven Mayer.
Read More
Grifols nears launch of clinical trial for potential COVID-19 treatment
Global biotherapeutics giant Grifols will soon start a clinical trial for what could become the next approved treatment for COVID-19. The trial will begin in February in Spain, where Grifols is headquartered. Here are the details.
Read More
At Clayton plant, Grifols begins phase 3 testing for COVID-19 treatment
Since April, Grifols has been collecting blood plasma donated by healthy people who have recovered from COVID-19. The therapy contains a high and consistent concentration of purified neutralizing antibodies.
Read More
As FDA authorizes plasma to combat COVID-19, Clayton plant working on possible treatment
President Donald Trump announced emergency authorization to treat COVID-19 patients with convalescent plasma. And that news could be good for Grifols, which operates a huge plasma production plant in Clayton.
Read More
At Clayton plant, Grifols produces first batch of potential COVID-19 treatment
Grifols, a global biotherapeutics company with major operations in North Carolina, has delivered the first batches of a therapeutic product manufactured in Clayton that could help prevent and treat COVID-19 infection.
Read More
Grifols begins manufacturing potential COVID-19 treatment at Clayton facility
Grifols, a global biotherapeutics company with major operations in North Carolina, has begun producing the first specific COVID-19 drug at its manufacturing campus in Clayton.
Read More
Grifols to invest $356M for new facility in Clayton, adding hundreds of jobs
The company is also building a $120 million purification and filling facility in Clayton that will mainly produce immune globulin and factor VIII protein therapies. The three-story, 150,000-square-foot facility, is scheduled to begin operating in 2022.
Read More
